Crossref
Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO
Multiple Sclerosis Journal · 29.04.2026
DOI: 10.1177/13524585261439655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 29.04.2026. Verfasst von James M Stankiewicz. Beteiligte Einrichtung: Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
ORCID-Profile: James M Stankiewicz
Zitieren
APA
Stankiewicz, J. M. (2026). Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261439655
Vancouver
Stankiewicz JM. Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261439655
BibTeX
@article{Stankiewicz2026,
author = {Stankiewicz, James M},
title = {Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO},
journal = {Multiple Sclerosis Journal},
year = {2026},
doi = {10.1177/13524585261439655}
}
EUVIMED